source
- Analyst doubts gold-based ALS therapy from Clene, calling it ineffectiveAdam Feuerstein, a senior biotech writer, published a piece in his Biotech Scorecard newsletter questioning a new ALS treatment. The company Clene is developing CNM-Au8, which it describes as a hi…
- Expert discusses uncertainties in melanoma adjuvant therapy sequencingDr. Mario Sznol, a professor of clinical medical oncology at the University of Miami, highlighted the difficulty of deciding whether to give adjuvant treatment to melanoma patients given the curren…